远大医药(00512)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

00512 远大医药

交易中 09-09 14:27:57

4.975

+0.025

+0.51%

最高5.020	最低4.905	成交量170.50万
今开4.945	昨收4.950	日振幅2.32%
总市值176.61亿	流通市值176.59亿	总股本35.50亿
成交额850.03万	换手率0.05%	流通股本35.50亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"00512","market":"HK","secType":"STK","nameCN":"远大医药","latestPrice":4.975,"timestamp":1788935248004,"preClose":4.95,"halted":0,"volume":1705000,"delay":0,"changeRate":0.0050505050505049425,"floatShares":3549571148,"shares":3550000000,"eps":0.3544,"marketStatus":"交易中","change":0.025,"latestTime":"09-09 14:27:57","open":4.945,"high":5.02,"low":4.905,"amount":8500260,"amplitude":0.023232,"askPrice":4.975,"askSize":10500,"bidPrice":4.965,"bidSize":7000,"shortable":3,"etf":0,"ttmEps":0.316754,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1788941400000},"marketStatusCode":2,"adr":0,"listingDate":819302400000,"exchange":"SEHK","adjPreClose":4.95,"dividendRate":0.03397,"openAndCloseTimeList":[[1788917400000,1788926400000],[1788930000000,1788940800000]],"volumeRatio":0.463972,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/00512","defaultTab":"news","newsList":[{"id":"2666307419","title":"【券商聚焦】国信证券维持远大医药（00512）优于大市评级 指核药板块高速放量","url":"https://stock-news.laohu8.com/highlight/detail?id=2666307419","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666307419?lang=zh_cn&edition=full","pubTime":"2026-09-09 14:00","pubTimestamp":1788933625,"startTime":"0","endTime":"0","summary":"金吾财讯 | 国信证券发布研报指，远大医药 2026年上半年实现收入63.89亿港元，同比增长3.2%；归母净利润10.62亿港元，扣除对Telix投资的公允价值变动和处置收益后，经调整经营性纯利9.73亿港元，同比下降6.6%。远大医药自2015年以来加速创新转型，已在核药抗肿瘤、心脑血管精准介入以及制药科技三个板块分别构建了“梯度化+差异化”的管线，期待核药板块的临床进展和商业化放量，维持“优于大市”评级。","market":"sg","thumbnail":"https://static.szfiu.com/news/20250109/YmQzNzBkZGZmOTg1MzM5MTQzMTA0Ng==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/YmQzNzBkZGZmOTg1MzM5MTQzMTA0Ng==.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":"299f0a9977df499f8ead781071e5e5e7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1991174","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00512","002736","KCE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665319142","title":"执行董事周超增持远大医药(00512)2.15万股 每股作价4.88港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2665319142","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665319142?lang=zh_cn&edition=full","pubTime":"2026-09-07 19:25","pubTimestamp":1788780313,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新数据显示，9月7日，执行董事周超增持远大医药(00512)2.15万股，每股作价4.88港元，总金额约为10.49万港元。增持后最新持股数目为53.25万股，最新持股比例为0.02%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1492964.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["00512","EWH","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665319128","title":"执行董事周超增持远大医药(00512.HK)2.15万股 每股作价4.88港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2665319128","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665319128?lang=zh_cn&edition=full","pubTime":"2026-09-07 19:25","pubTimestamp":1788780313,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1191","00512"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120588679","title":"远大医药：周超增持，好仓比例升至0.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=1120588679","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1120588679?lang=zh_cn&edition=full","pubTime":"2026-09-07 17:22","pubTimestamp":1788772955,"startTime":"0","endTime":"0","summary":"周超于2026年9月7日以每股均价4.88港元买入远大医药股份2.15万股，涉资约10.49万港元。周超此次增持前持有远大医药好仓51.10万股，占比0.01%；增持后持股量为53.25万股，好仓比例升至0.02%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"f7700173111443e192ac74957e46cb69","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00512"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1137380893","title":"远大医药更新2026年8月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1137380893","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1137380893?lang=zh_cn&edition=full","pubTime":"2026-09-02 16:41","pubTimestamp":1788338478,"startTime":"0","endTime":"0","summary":"远大医药2026年9月2日发布了截至2026年8月31日止的证券变动月报表。公告显示，公司报告期内注册股本维持不变，未发生新增发行、股份购回或注销等活动。已发行普通股数量为3,549,571,148股，库藏股份数量为0股，与上月底持平，股本总数保持稳定。公告还显示，公司目前公众持股量已符合香港联交所规定的最低公众持股量要求。本次公告由公司秘书傅天忠签署。远大医药将继续关注市场动态，严格遵守合规要求。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00512"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662563707","title":"董事会主席唐纬坤增持远大医药(00512)5.6万股 每股作价约5.31港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2662563707","media":"智通财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662563707?lang=zh_cn&edition=full","pubTime":"2026-08-27 19:44","pubTimestamp":1787831090,"startTime":"0","endTime":"0","summary":"8月27日，董事会主席唐纬坤增持远大医药(00512)5.6万股，每股作价5.3094港元，总金额约为29.73万港元。","market":"hk","thumbnail":"https://img.zhitongcaijing.com/image/20260827/20260827194516_45786.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260827/20260827194516_45786.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1487260.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK1191","00512","EWH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662773051","title":"远大医药中期净利同比下滑近11%，Telix投资贡献同比缩水超六千万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2662773051","media":"深圳商报·读创","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662773051?lang=zh_cn&edition=full","pubTime":"2026-08-27 14:17","pubTimestamp":1787811429,"startTime":"0","endTime":"0","summary":"8月26日，远大医药（00512.HK）发布2026年中期业绩公告，上半年公司实现营业收入约63.9亿港元，同比增长3.2%；经调整经营性纯利约9.7亿港元。其中，核药抗肿瘤诊疗及心脑血管精准介入诊疗科技产品取得收益约港币7.45亿元，同比上涨约29%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608273856251645.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608273856251645.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["EWH","00512","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1159072296","title":"远大医药宣布不派发中期股息","url":"https://stock-news.laohu8.com/highlight/detail?id=1159072296","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1159072296?lang=zh_cn&edition=full","pubTime":"2026-08-27 00:24","pubTimestamp":1787761482,"startTime":"0","endTime":"0","summary":"8月26日（路透社）——远大医药集团有限公司<0512.HK>公告要点如下：\n公司明确表示，本年度中期未派发或宣派任何股息。\n上半年归属于股东的净利润达到10.6154亿港元。\n同期，公司收入录得63.8891亿港元。\n如需进一步了解该公司详情，请参阅股票代码0512.HK的相关报道。\n（路透社简报专线）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","00512"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662471765","title":"远大医药(00512.HK)上半年核药抗肿瘤板块收益大增55.4% 管线储备充足 静待 2027‑2028 研发里程碑集中兑现","url":"https://stock-news.laohu8.com/highlight/detail?id=2662471765","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662471765?lang=zh_cn&edition=full","pubTime":"2026-08-26 21:49","pubTimestamp":1787752194,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["00512","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662271730","title":"远大医药(00512)上半年核药营收同比增长55%，多板块业务协同迸发创新活力","url":"https://stock-news.laohu8.com/highlight/detail?id=2662271730","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662271730?lang=zh_cn&edition=full","pubTime":"2026-08-26 21:45","pubTimestamp":1787751921,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，2026年上半年，中国医药行业已进入创新成果集中验证的发展阶段。核药诊疗一体化闭环成型，商业化与研发双轮驱动核药抗肿瘤诊疗是远大医药最亮眼的业务板块，上半年取得收入约6.6亿港元，同比增长55%，持续保持高速增长。上半年，两款重要1.1类中药创新药取得新的里程","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1486463.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["00512"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662717835","title":"远大医药(00512.HK)披露2026半年报：核药产业优势夯实全球竞争力，多板块协同打开增长新空间","url":"https://stock-news.laohu8.com/highlight/detail?id=2662717835","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662717835?lang=zh_cn&edition=full","pubTime":"2026-08-26 21:42","pubTimestamp":1787751731,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1191","00512"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1170552830","title":"远大医药（00512）将于8月26日召开董事会审议2026年中期业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=1170552830","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1170552830?lang=zh_cn&edition=full","pubTime":"2026-08-10 17:05","pubTimestamp":1786352739,"startTime":"0","endTime":"0","summary":"远大医药（00512）8月10日晚间公告称，公司董事会会议将于2026年8月26日（星期三）举行，主要议程包括审议并批准公司及其附属公司截至2026年6月30日止六个月的中期业绩，以及处理其他相关事项（如有）。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00512"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658660609","title":"港股异动 | 远大医药(00512)早盘涨超5% 自研GPN01530-2斩获美国FDA快速通道资格","url":"https://stock-news.laohu8.com/highlight/detail?id=2658660609","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658660609?lang=zh_cn&edition=full","pubTime":"2026-08-10 09:44","pubTimestamp":1786326245,"startTime":"0","endTime":"0","summary":"消息面上，8月9日，远大医药发布公告，集团自主研发的用于诊断实体瘤的全球创新放射性核素偶联药物  GPN01530-2近日获得美国食品药品监督管理局授予的快速通道资格。FDA 设立快速通道机制，旨在加速和促进用于治疗当前并无有效治疗方案的严重或危及生命的疾病、且展示出有满足这一疾病当前未被满足的医疗需求潜力的新药的评审过程。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1477795.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["KCAI","BK4588","00512","VXUS","BK4585","BK1191","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658672042","title":"国产FAP核药获美国FDA加速审批通道 远大医药依托一体化核药产业链角逐核药市场","url":"https://stock-news.laohu8.com/highlight/detail?id=2658672042","media":"证券日报","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658672042?lang=zh_cn&edition=full","pubTime":"2026-08-09 19:54","pubTimestamp":1786276440,"startTime":"0","endTime":"0","summary":"远大医药集团有限公司（以下简称“远大医药”）发布公告称，公司FAP靶点创新核药GPN01530-2已获得美国FDA授予快速通道资格（FastTrackDesignation，FTD）。FTD资格主要授予用于治疗严重疾病且有潜力解决未满足医疗需求的在研药物，旨在加速高价值在研药物的审评进程。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608093835965072.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608093835965072.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1191","00512","LABU","BK4588","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658728656","title":"中国FAP靶向实体瘤诊断核药首次获FDA快速通道资格认定，远大医药(00512)自研产品直击泛实体瘤千亿美元未满足市场需求","url":"https://stock-news.laohu8.com/highlight/detail?id=2658728656","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658728656?lang=zh_cn&edition=full","pubTime":"2026-08-09 18:18","pubTimestamp":1786270729,"startTime":"0","endTime":"0","summary":"作为核药龙头企业，远大医药近日在该领域再次取得重磅突破，公司FAP靶点创新核药GPN01530-2已获得美国FDA授予快速通道资格，成为全球首个获得FDA快速通道认定的实体瘤FAP靶点诊断核药。据悉，GPN01530-2此前已获FDA批准开展用于诊断实体瘤的I/II期临床研究，此次其获快速通道资格认定，标志着美国监管机构认可该产品在实体瘤诊断的重要潜力，有望加快GPN01530-2未来开发及上市进程，尽早惠及全球患者。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1477702.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","00512","BK4588","LABU","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1114475235","title":"远大医药：自主研发全球创新放射性核素偶联药物GPN01530-2获FDA快速通道资格","url":"https://stock-news.laohu8.com/highlight/detail?id=1114475235","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1114475235?lang=zh_cn&edition=full","pubTime":"2026-08-09 18:12","pubTimestamp":1786270330,"startTime":"0","endTime":"0","summary":"远大医药近日宣布，其独立自主研发、具备全球创新性的放射性核素偶联药物——GPN01530-2，已获得美国食品药品监督管理局授予的快速通道资格。GPN01530-2作为一款前沿的放射性核素靶向治疗药物，其设计旨在精准递送辐射剂量至肿瘤细胞，同时最大限度地减少对健康组织的损伤。远大医药在核药领域的持续深耕，正逐步构建起涵盖研发、生产及商业化的完整产业链，而此次GPN01530-2的突破，无疑进一步巩固了其在全球创新药竞争格局中的位置。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","00512"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109236483","title":"远大医药（00512）自主研发放射性核素偶联药物GPN01530-2获FDA快速通道资格","url":"https://stock-news.laohu8.com/highlight/detail?id=1109236483","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1109236483?lang=zh_cn&edition=full","pubTime":"2026-08-09 18:11","pubTimestamp":1786270277,"startTime":"0","endTime":"0","summary":"8月9日，远大医药公告，其自主研发的靶向成纤维细胞活化蛋白小分子放射性核素偶联药物GPN01530-2已获美国食品药品监督管理局授予快速通道资格。此前，GPN01530-2已获FDA批准开展用于诊断实体瘤的I/II期临床研究。公告显示，GPN01530-2通过特异性靶向FAP，为多种恶性实体瘤的诊断提供新方案。远大医药提醒，GPN01530-2处于研发阶段，能否最终获批上市并实现商业化存在不确定性。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00512"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658723636","title":"远大医药：自主研发放射性核素药物GPN01530-2获FDA快速通道资格","url":"https://stock-news.laohu8.com/highlight/detail?id=2658723636","media":"南方财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658723636?lang=zh_cn&edition=full","pubTime":"2026-08-09 18:07","pubTimestamp":1786270020,"startTime":"0","endTime":"0","summary":"南财智讯8月9日电，远大医药（00512.HK）发布自愿公告，公司自主研发的全球创新放射性核素偶联药物GPN01530-2近日获得美国食品药品监督管理局（FDA）授予的快速通道资格（FastTrackDesignation），用于诊断实体瘤。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608093835946655.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608093835946655.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1191","LABU","00512","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132632271","title":"远大医药2026年7月股份变动月报表：股本维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1132632271","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1132632271?lang=zh_cn&edition=full","pubTime":"2026-08-03 17:33","pubTimestamp":1785749629,"startTime":"0","endTime":"0","summary":"远大医药集团有限公司（股票代码：00512）于2026年8月3日披露截至2026年7月31日的证券变动月报表。公告显示，公司本月法定股本总额保持在港币10亿元（1000,000,000），对应的注册股本为1000亿股，面值为每股港币0.01，较上月底未发生变化。\n已发行股份方面，远大医药集团有限公司于报告期内总计拥有3,549,571,148股股份，库藏股数量维持为零，已发行股份总数与上月持平，未有新增发行、回购或注销股份的情形，也不存在与期权、权证及可换股债券相关的变动。公司表示将继续遵守香港联合交易所有限公司证券上市规则及相关法律法规，公告由公司秘书傅天忠签署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00512"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1113347739","title":"远大医药（00512）公告自2026年8月3日起变更百慕大注册及股份过户登记处地址","url":"https://stock-news.laohu8.com/highlight/detail?id=1113347739","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1113347739?lang=zh_cn&edition=full","pubTime":"2026-07-31 17:06","pubTimestamp":1785488764,"startTime":"0","endTime":"0","summary":"远大医药集团有限公司（股票代码：00512）7月31日在港交所公告称，公司位于百慕大的主要股份过户登记处及注册办事处地址将自2026年8月3日（星期一）起变更为：Richmond House, 12 Par-la-Ville Road, Hamilton HM 08, Bermuda。\n公告显示，截至公告日，公司董事会由以下人员组成：执行董事唐纬坤博士、周超先生、杨光先生及林芷伊女士；独立非执行董事苏彩云女士、邢丽娜博士、裴更博士及胡野碧先生。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00512"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.chinagrandpharm.com","stockEarnings":[{"period":"1week","weight":-0.0149},{"period":"1month","weight":-0.0544},{"period":"3month","weight":0.0043},{"period":"6month","weight":-0.2994},{"period":"1year","weight":-0.4499},{"period":"ytd","weight":-0.3476}],"compareEarnings":[{"period":"1week","weight":-0.0005},{"period":"1month","weight":-0.0137},{"period":"3month","weight":0.0373},{"period":"6month","weight":-0.0155},{"period":"1year","weight":-0.0124},{"period":"ytd","weight":-0.0122}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"远大医药集团有限公司是一家主要从事医药业务的投资控股公司。该公司主要从事制造及销售医药制剂及医疗器械。该公司还从事制造及销售生物技术产品、健康产品、精品原料药和其他产品。该公司的主要产品包括核药抗肿瘤诊疗及心脑血管介入诊疗科技产品。","yearOnYearQuotes":[{"month":1,"riseRate":0.451613,"avgChangeRate":0.084145},{"month":2,"riseRate":0.709677,"avgChangeRate":0.104891},{"month":3,"riseRate":0.387097,"avgChangeRate":0.015748},{"month":4,"riseRate":0.612903,"avgChangeRate":0.013455},{"month":5,"riseRate":0.451613,"avgChangeRate":0.076266},{"month":6,"riseRate":0.354839,"avgChangeRate":-0.048729},{"month":7,"riseRate":0.387097,"avgChangeRate":-0.011524},{"month":8,"riseRate":0.387097,"avgChangeRate":0.005503},{"month":9,"riseRate":0.451613,"avgChangeRate":-0.038472},{"month":10,"riseRate":0.5,"avgChangeRate":-0.014639},{"month":11,"riseRate":0.5,"avgChangeRate":0.085072},{"month":12,"riseRate":0.5,"avgChangeRate":-0.007406}],"exchange":"SEHK","name":"远大医药","nameEN":"GRAND PHARMA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"远大医药(00512)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供远大医药(00512)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"远大医药,00512,远大医药股票,远大医药股票老虎,远大医药股票老虎国际,远大医药行情,远大医药股票行情,远大医药股价,远大医药股市,远大医药股票价格,远大医药股票交易,远大医药股票购买,远大医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"远大医药(00512)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供远大医药(00512)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}